Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Summary

This randomized pilot clinical trial studies the side effects and best dose of naloxegol and to see how well it works in treating patients with stage IIIB-IV non-small cell lung cancer. Naloxegol may relieve some of the side effects of opioid pain medication and fight off future growth in the cancer.

Timeline

Start

2018-03-23

Primary completion

2021-01-04

Completion

2023-04-01

Publications

• Gupta P, Gupta K, Dockter T, Harlos E, Chow S, Subbiah N, Ruddy KJ, Bazhenova L, Terstriep S, Huang CH, Kratzke RA, Vokes EE, Loprinzi CL. Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study. Cancers (Basel). 2026 Jan 25;18(3):373. doi: 10.3390/cancers18030373.

Drugs

Indications